Brief: Marker Therapeutics Receives Approval From U.S. Adopted Name Council And International Nonproprietary Names Expert Committee For “Neldaleucel” As Nonproprietary Name For MT-601
22/01/2024 12:49
Jan 22 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS RECEIVES APPROVAL FROM UNITED STATES
ADOPTED
NAME (USAN) COUNCIL AND INTERNATIONAL NONPROPRIETARY NAMES (INN)
EXPERT COMMITTEE FOR “NELDALEUCEL” AS NONPROPRIETARY NAME FOR
MT-601
Source text for Eikon: ID:nGNX7zyvPf
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79